Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • FDA Flags Major GMP Violations at Fresenius Kabi Sterile Injectable Facility; Recalls and Corrective Actions Under Review
    2 October 2026

    FDA Flags Major GMP Violations at Fresenius Kabi Sterile Injectable Facility; Recalls and Corrective Actions Under Review

    The U.S. Food and Drug Administration (FDA) has issued a warning letter to Fresenius Kabi USA LLC over significant Current Good Manufacturing Practice (CGMP) violations identified at the company's sterile drug manufacturing facility in Melrose Park, Illinois.
  • MSD’s Tulisokibart Hits Key Endpoints in Phase 2b HS Study
    1 October 2026
    MSD’s Tulisokibart Hits Key Endpoints in Phase 2b HS Study
    MSD announced the first presentation of results from MK-7240-012, a Phase 2b multicenter, randomized, double-blind, placebo-controlled trial evaluating tulisokibart, an investigational humanized monoclonal antibody targeting tumor necrosis factor-like cytokine 1A (TL1A), in patients with moderate to severe hidradenitis suppurativa (HS).
  • Jagsonpal Pharmaceuticals to Acquire Group Pharma’s Wellness Portfolio in ₹46.7 Crore Deal
    30 September 2026
    Jagsonpal Pharmaceuticals to Acquire Group Pharma’s Wellness Portfolio in ₹46.7 Crore Deal

    Jagsonpal Pharmaceuticals Limited has entered into a Business Transfer Agreement (BTA) with Group Pharmaceuticals Limited to acquire its Wellness Portfolio, in a transaction that could have a total consideration of up to ₹46.7 crore.

    According to the company’s regulatory disclosure dated September 23, 2026, the acquisition will be undertaken on a going-concern basis through a slump sale. Jagsonpal said the move is aimed at strengthening its pharmaceutical portfolio, expanding its presence across relevant therapeutic segments and increasing its market reach.

  • Foundayo Shows Greater Weight Loss and A1C Reduction Than Oral Semaglutide
    30 September 2026
    Foundayo Shows Greater Weight Loss and A1C Reduction Than Oral Semaglutide
    Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) announced results from a new analysis showing that Foundayo (orforglipron) 17.2 mg was associated with significantly greater weight loss and better blood sugar control than oral semaglutide 25 mg in adults with type 2 diabetes.
  • Ozempic Linked to Lower Cardiovascular Risk Than Mounjaro in Type 2 Diabetes
    30 September 2026
    Ozempic Linked to Lower Cardiovascular Risk Than Mounjaro in Type 2 Diabetes
    Novo Nordisk today announced new retrospective real-world evidence in adults with type 2 diabetes treated with once-weekly semaglutide injection 1 mg.
  • 6th National Pharmacovigilance Week 2026 at Saveetha College of Pharmacy
    30 September 2026
    6th National Pharmacovigilance Week 2026 at Saveetha College of Pharmacy

    In observance of the 6th National Pharmacovigilance Week 2026, the Department of Pharmacy Practice, Saveetha College of Pharmacy, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai, in collaboration with the Indian Pharmaceutical Association – Hospital Pharmacy Division (IPA-HPD), organized a series of awareness and educational programmes from September 17 to 23, 2026.

  • DTAB Recommends Separate GMP Requirements for Clinical and Non-Clinical Drug Manufacturing
    30 September 2026
    DTAB Recommends Separate GMP Requirements for Clinical and Non-Clinical Drug Manufacturing
    The Drugs Technical Advisory Board, DTAB, has recommended changes to the regulatory requirements for manufacturing drugs intended for clinical trials, bioavailability and bioequivalence studies, analytical testing and non-clinical studies.
  • Roche Reports Positive Phase III Results for Sefaxersen in IgA Nephropathy
    29 September 2026
    Roche Reports Positive Phase III Results for Sefaxersen in IgA Nephropathy
    Roche has announced positive interim results from its ongoing Phase III IMAgINATION study evaluating sefaxersen, an investigational treatment for adults living with primary IgA nephropathy (IgAN).
  • AbbVie’s JUVMO Gets FDA Approval for Parkinson’s Disease: New D1/D5 Targeted Treatment Approved in the U.S.
    29 September 2026
    AbbVie’s JUVMO Gets FDA Approval for Parkinson’s Disease: New D1/D5 Targeted Treatment Approved in the U.S.

    AbbVie’s JUVMO (tavapadon) has received approval from the U.S. Food and Drug Administration (FDA) for the treatment of Parkinson’s disease in adults. The once-daily oral medicine introduces a different approach to dopamine-based treatment by selectively targeting D1/D5 receptors.

    AbbVie announced on September 28, 2026, that the FDA approved JUVMO tablets for adults with Parkinson’s disease. The company describes JUVMO as the first and only selective D1/D5 receptor agonist approved for adults with Parkinson’s disease.

  • Eli Lilly Sets 2040 Goal to Expand Diabetes and Obesity Treatment Access in Developing Markets
    29 September 2026
    Eli Lilly Sets 2040 Goal to Expand Diabetes and Obesity Treatment Access in Developing Markets

    Eli Lilly and Company has announced the launch of the Lilly Change the Course Commitment, a new global health initiative aimed at addressing gaps in access to diabetes and obesity treatments in low- and middle-income countries (LMICs). The company has set a goal of achieving parity in the number of patients treated with its diabetes and obesity medicines in resource-limited settings and high-income countries before 2040.

Subscribe to Pharma News